A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Treatment, Three 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 300mg as Compared to Adding Montelukast 10mg or Placebo Tablets QD to Fluticasone Propionate/Salmeterol 250/50mcg Diskus BID.

Trial Profile

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Treatment, Three 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 300mg as Compared to Adding Montelukast 10mg or Placebo Tablets QD to Fluticasone Propionate/Salmeterol 250/50mcg Diskus BID.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2016

At a glance

  • Drugs Fiboflapon (Primary) ; Montelukast; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 21 Oct 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
    • 21 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Aug 2011 Planned end date changed from 1 Jul 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top